Physician profile
Jack M Smith
NPI 1346687720
$324,208.66
in general payments reported to CMS, 2019-2025
51 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $16.95 · 2020: $1,633 · 2021: $1,928 · 2022: $6,553 · 2023: $13K · 2024: $145K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $247K · Travel and Lodging: $35K · Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $247,230.00 |
| Travel and Lodging | $35,155.69 |
| Food and Beverage | $14,325.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,216.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $216,960.04 | 2021-2025 | |
| Abbott Laboratories | $32,526.54 | 2020-2025 | Proclaim, Eterna, Penta |
| Stryker Corporation | $24,638.43 | 2023-2025 | Mild Device Kit, Optablate, Omnicurve |
| Medtronic, INC. | $21,610.84 | 2021-2025 | Accurian, Intellis Adaptivestim, Osteocool Rf Ablation System |
| Vertos Medical, INC. | $7,349.79 | 2021-2024 | Mild Device Kit |
| Biotronik Nro, INC. | $5,699.25 | 2023-2024 | Prospera, Biotronik |
| Painteq LLC | $5,269.14 | 2021-2024 | Painteq |
| Boston Scientific Corporation | $2,850.82 | 2019-2025 | Intracept, General - Pain Management, Infinion 16 |
| Relievant Medsystems, INC. | $1,858.33 | 2021-2023 | Intracept |
| Intuitive Surgical, INC. | $1,632.81 | 2023-2025 | Da Vinci Surgical System |
| Saluda Medical Americas, INC. | $1,455.62 | 2022-2025 | Evoke, Evoke Scs |
| Averitas Pharma INC. | $306.60 | 2023-2025 | Qutenza |
| Mml US, INC. | $281.39 | 2022-2024 | Reactiv8 |
| Foundation Fusion Solutions, LLC | $150.95 | 2021-2023 | |
| Curonix LLC | $131.25 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $114.66 | 2022-2023 | Senza |
| Orthofundamentals, LLC | $113.30 | 2025 | Trellis Si Joint Fusion System |
| Nalu Medical, INC. | $101.08 | 2022-2024 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $88.87 | 2020 | |
| Abbvie INC. | $77.23 | 2023-2024 | Botox |
| Stimwave Technologies Incorporated | $69.00 | 2021 | |
| Genentech USA, INC. | $64.89 | 2023-2024 | Ocrevus, Enspryng |
| Trevena, INC. | $64.37 | 2023 | Olinvyk |
| Ani Pharmaceuticals, INC. | $63.10 | 2024 | Purified Cortrophin Gel |
| Providence Medical Technology, INC. | $56.36 | 2024 | |
| Argenx US, INC. | $54.63 | 2024 | Vyvgart |
| Biogen, INC. | $52.82 | 2025 | Vumerity, Tysabri |
| Ucb, INC. | $41.90 | 2022-2024 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $40.26 | 2024 | Austedo Xr |
| Spr Therapeutics, INC | $39.02 | 2020 | |
| Lundbeck LLC | $34.92 | 2024-2025 | Vyepti |
| Neurelis, INC. | $32.81 | 2022-2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $32.13 | 2023 | Gammagard |
| Kowa Pharmaceuticals America, INC. | $27.02 | 2022-2023 | Seglentis |
| Lilly USA, LLC | $24.15 | 2023 | Emgality |
| International Rehabilitative Sciences, INC | $23.63 | 2025 | Rs-4i Plus With Intersperse |
| Neurocrine Biosciences, INC. | $22.77 | 2024 | Ingrezza |
| Electronic Waveform Lab, INC. | $21.76 | 2024 | |
| Redhill Biopharma INC. | $21.62 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $21.52 | 2022 | |
| Axsome Therapeutics, INC. | $20.53 | 2025 | Symbravo |
| Supernus Pharmaceuticals, INC. | $18.93 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.86 | 2023 | Lyvispah |
| Vanda Pharmaceuticals INC. | $18.56 | 2024 | Ponvory |
| Amgen INC. | $17.24 | 2022 | |
| Tersera Therapeutics LLC | $16.76 | 2023 | Prialt |
| Impel Pharmaceuticals LLC | $16.63 | 2024 | Trudhesa |
| Collegium Pharmaceutical, INC. | $14.76 | 2024 | Belbuca |
| Azurity Pharmaceuticals, INC. | $13.95 | 2022 | |
| Impel Pharmaceuticals INC. | $13.91 | 2022 | |
| Grt US Holding, INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$18,876.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.